Should statins be given routinely before carotid endarterectomy

Research output: Contribution to journalArticle

Abstract

Statins belong to a class of drugs known to inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG CoA) reductase, and block hepatic cholesterol synthesis. Statins have been found to be highly effective in primary and secondary stroke prevention among medically managed patients with cardiovascular disease, and it appears that this benefit is largely owing to the non-cholesterol-lowering, so called pleiotropic, effects of statins. Over the past decade, agents such as beta-blockers, aspirin, or other antiplatelet medications have proven to reduce the incidence of adverse postoperative outcomes among vascular surgical patients and have rightfully assumed a place in our overall therapeutic armamentarium. There is growing evidence that statins may be especially effective in reducing cardiovascular morbidity and improving outcome following major vascular surgery. A recent study from Johns Hopkins Hospital demonstrated a threefold reduction in the rate of perioperative stroke (P <.05) and fivefold reduction of perioperative mortality (P <.05) among 1566 patients undergoing carotid endarterectomy (CEA). This benefit was confirmed in a series of 3360 CEAs performed at multiple hospitals throughout western Canada. Statin use was independently associated with a 75% reduction (OR: 0.25; 95%CI: 0.07-0.90) in the odds of death and a 45% reduction (OR: 0.55; 95% CI: 0.32-0.95) in the odds of ischemic stroke or death among patients with symptomatic carotid disease. A number of the pleiotropic effects of statin medications may be responsible for these clinical observations. Further work is necessary to better elucidate these mechanisms, as well as to determine the optimal agents, dosing, and timing of drug administration among patients undergoing carotid interventions. Nevertheless, in light of these data a strong case can be made to start patients on statin medications prior to CEA if time permits.

Original languageEnglish (US)
Pages (from-to)240-245
Number of pages6
JournalPerspectives in Vascular Surgery and Endovascular Therapy
Volume19
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Carotid Endarterectomy
Stroke
Blood Vessels
Secondary Prevention
Pharmaceutical Preparations
Aspirin
Canada
Oxidoreductases
Cardiovascular Diseases
Cholesterol
Morbidity
Mortality
Liver
Incidence

Keywords

  • Carotid endarterectomy
  • Statins
  • Vulnerable plaque

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Should statins be given routinely before carotid endarterectomy. / Perler, Bruce Alan.

In: Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 19, No. 3, 09.2007, p. 240-245.

Research output: Contribution to journalArticle

@article{9b99bf73c5564610bd1a13816b5fc329,
title = "Should statins be given routinely before carotid endarterectomy",
abstract = "Statins belong to a class of drugs known to inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG CoA) reductase, and block hepatic cholesterol synthesis. Statins have been found to be highly effective in primary and secondary stroke prevention among medically managed patients with cardiovascular disease, and it appears that this benefit is largely owing to the non-cholesterol-lowering, so called pleiotropic, effects of statins. Over the past decade, agents such as beta-blockers, aspirin, or other antiplatelet medications have proven to reduce the incidence of adverse postoperative outcomes among vascular surgical patients and have rightfully assumed a place in our overall therapeutic armamentarium. There is growing evidence that statins may be especially effective in reducing cardiovascular morbidity and improving outcome following major vascular surgery. A recent study from Johns Hopkins Hospital demonstrated a threefold reduction in the rate of perioperative stroke (P <.05) and fivefold reduction of perioperative mortality (P <.05) among 1566 patients undergoing carotid endarterectomy (CEA). This benefit was confirmed in a series of 3360 CEAs performed at multiple hospitals throughout western Canada. Statin use was independently associated with a 75{\%} reduction (OR: 0.25; 95{\%}CI: 0.07-0.90) in the odds of death and a 45{\%} reduction (OR: 0.55; 95{\%} CI: 0.32-0.95) in the odds of ischemic stroke or death among patients with symptomatic carotid disease. A number of the pleiotropic effects of statin medications may be responsible for these clinical observations. Further work is necessary to better elucidate these mechanisms, as well as to determine the optimal agents, dosing, and timing of drug administration among patients undergoing carotid interventions. Nevertheless, in light of these data a strong case can be made to start patients on statin medications prior to CEA if time permits.",
keywords = "Carotid endarterectomy, Statins, Vulnerable plaque",
author = "Perler, {Bruce Alan}",
year = "2007",
month = "9",
doi = "10.1177/1531003507304436",
language = "English (US)",
volume = "19",
pages = "240--245",
journal = "Perspectives in Vascular Surgery and Endovascular Therapy",
issn = "1531-0035",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Should statins be given routinely before carotid endarterectomy

AU - Perler, Bruce Alan

PY - 2007/9

Y1 - 2007/9

N2 - Statins belong to a class of drugs known to inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG CoA) reductase, and block hepatic cholesterol synthesis. Statins have been found to be highly effective in primary and secondary stroke prevention among medically managed patients with cardiovascular disease, and it appears that this benefit is largely owing to the non-cholesterol-lowering, so called pleiotropic, effects of statins. Over the past decade, agents such as beta-blockers, aspirin, or other antiplatelet medications have proven to reduce the incidence of adverse postoperative outcomes among vascular surgical patients and have rightfully assumed a place in our overall therapeutic armamentarium. There is growing evidence that statins may be especially effective in reducing cardiovascular morbidity and improving outcome following major vascular surgery. A recent study from Johns Hopkins Hospital demonstrated a threefold reduction in the rate of perioperative stroke (P <.05) and fivefold reduction of perioperative mortality (P <.05) among 1566 patients undergoing carotid endarterectomy (CEA). This benefit was confirmed in a series of 3360 CEAs performed at multiple hospitals throughout western Canada. Statin use was independently associated with a 75% reduction (OR: 0.25; 95%CI: 0.07-0.90) in the odds of death and a 45% reduction (OR: 0.55; 95% CI: 0.32-0.95) in the odds of ischemic stroke or death among patients with symptomatic carotid disease. A number of the pleiotropic effects of statin medications may be responsible for these clinical observations. Further work is necessary to better elucidate these mechanisms, as well as to determine the optimal agents, dosing, and timing of drug administration among patients undergoing carotid interventions. Nevertheless, in light of these data a strong case can be made to start patients on statin medications prior to CEA if time permits.

AB - Statins belong to a class of drugs known to inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG CoA) reductase, and block hepatic cholesterol synthesis. Statins have been found to be highly effective in primary and secondary stroke prevention among medically managed patients with cardiovascular disease, and it appears that this benefit is largely owing to the non-cholesterol-lowering, so called pleiotropic, effects of statins. Over the past decade, agents such as beta-blockers, aspirin, or other antiplatelet medications have proven to reduce the incidence of adverse postoperative outcomes among vascular surgical patients and have rightfully assumed a place in our overall therapeutic armamentarium. There is growing evidence that statins may be especially effective in reducing cardiovascular morbidity and improving outcome following major vascular surgery. A recent study from Johns Hopkins Hospital demonstrated a threefold reduction in the rate of perioperative stroke (P <.05) and fivefold reduction of perioperative mortality (P <.05) among 1566 patients undergoing carotid endarterectomy (CEA). This benefit was confirmed in a series of 3360 CEAs performed at multiple hospitals throughout western Canada. Statin use was independently associated with a 75% reduction (OR: 0.25; 95%CI: 0.07-0.90) in the odds of death and a 45% reduction (OR: 0.55; 95% CI: 0.32-0.95) in the odds of ischemic stroke or death among patients with symptomatic carotid disease. A number of the pleiotropic effects of statin medications may be responsible for these clinical observations. Further work is necessary to better elucidate these mechanisms, as well as to determine the optimal agents, dosing, and timing of drug administration among patients undergoing carotid interventions. Nevertheless, in light of these data a strong case can be made to start patients on statin medications prior to CEA if time permits.

KW - Carotid endarterectomy

KW - Statins

KW - Vulnerable plaque

UR - http://www.scopus.com/inward/record.url?scp=38449097022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449097022&partnerID=8YFLogxK

U2 - 10.1177/1531003507304436

DO - 10.1177/1531003507304436

M3 - Article

C2 - 17911547

AN - SCOPUS:38449097022

VL - 19

SP - 240

EP - 245

JO - Perspectives in Vascular Surgery and Endovascular Therapy

JF - Perspectives in Vascular Surgery and Endovascular Therapy

SN - 1531-0035

IS - 3

ER -